How Bora Pharmaceuticals is moving into biologics and attempting to crack North America

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Biologics Manufacturing Supply chain Pharmacology

Bora Pharmaceuticals is a pharmaceutical company that provides solutions for the development, manufacturing, and packaging of pharmaceutical products. In the large molecule space, it offers comprehensive services from the development of mammalian cell lines through cGMP production of drug substance.

BPR: What is Bora planning at Bio International in Boston?

Bio Boston will be a fantastic opportunity for Bora to showcase our capabilities, technologies, and service and we are also looking to increase our visibility and enhance brand awareness within the industry.

Having a new brand in Bora Biologics requires legwork needed to inform the customer base about our team, facilities, capabilities, and services.

We are excited to participate in BIO this year to do just that – have meaningful conversations, build the brand, build new relationships, and strengthen existing ones.

BPR: How is Bora navigating the current contract manufacturing scene?

Bora is focused on being a CDMO that plays to its strengths within the marketplace. 

We also analyze the market with respect to technology and regulatory trends to stay current with our offering and by understanding what different market segments need by way of support so we can focus on the right solutions for our clients – whether they be large biopharma or small virtual companies.

BPR: Could you tell us about your move into the biologics space last year?

Bora Biologics entered the CMO space last July through the acquisition of facilities and retention of personnel involved in a drug development company.

We leveraged these assets to begin helping clients navigate the CMC process with technical expertise, very strong quality systems, and smartly designed development and manufacturing capabilities.

What is important and different about Bora Biologics is our significant expertise in analytical development and validation for biologics as well as our team that has been together on average of 10 years - something unheard of in the CDMO space.

This combination helps us accelerate development activities from cell line through GMP production of drug substance for our clients and their patients.

BPR: Does Bora have plans to extend its business into North America?

Having a physical presence in the USA enables Bora to be closer to its American clients. This proximity can enhance customer service, facilitate faster response times, and strengthen relationships with clients who prefer local or regional partners.

Operating in multiple locations, including the USA, allows Bora to diversify its geographical footprint.

This diversification helps spread business risks by reducing dependency on a single market or region, minimizing the impact of any localized disruptions or market fluctuations.

Having multiple locations, including the USA, will enhance the organizations competitiveness by offering clients a wider range of services, geographical coverage, and the ability to support their needs on a global scale.

Related topics Biopharma Culture Pipelines

Related news

Show more

Follow us